Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Anne,
I don't know why it is even sensible to pay the website fees if the phone number on the website comes up disconnected.
I called the phone # a week ago and it's disconnected. So whoever,(if ever) is processing the Ancestry is either not maintaining the website or is another company using DNAG's name. There is also talk on other boards of Illumina suing the company for quite a bit over unpaid delivery of kits. Don't know if it's true. I've got 4 million shares that beg for some stupid miracle. Or at least a sideshow, lol.
Frog,
First you say the rights have been transferred or sold to the "group" (or, D.Gannon et el) and then you say the revenues would go to the German Financier. I would be interested in how you have access to the actual agreement between the two and how you know that the revenues "all" go to someone else.
That is a very large assumption. I would "assume" myself that you would know none of the particulars of such an agreement; but you are free to enlighten us without the usual assumptions.
That being said, it is true that the science is limited and the sales would be minimal. Nevertheless, this company is not "dead", eh?
Please, give us some particulars with some creditable facts.
The gist:
DNA Diagnostics Center announces the release of AncestrybyDNA™, a unique DNA test that reveals a person's ancestral origins.
Fairfield, Ohio (PRWEB) November 13, 2009 -- DNA Diagnostics Center (“DDC”), a DNA testing services company headquartered in Fairfield, Ohio, announces its release of AncestrybyDNA™, a unique DNA test that reveals an individual’s ancestral origins.
Through an exclusive worldwide licensing agreement with DNA Print Genomics, DNA Diagnostics Center (DDC) is launching a test that can identify 176 unique Ancestral Informative Markers in human DNA"
The problem is, who sold the license to them?
None of this makes sense.
nobody seems to know nuttin'
No, You.
idiot?
Seeing as some of you still visit here from time to time, who do you think is buying one to two million shares a day for months on end? And why?
As I recall, there are 4 different Tony Fradakis' , 3 of which are businessmen. Maybe a clarification is due. Farts aside, of course.
And some things NEVER change.
That is, if Frudakis hasn't taken the technology to Penn State and left DNAPrint in the dust. It would be nice to know what he is doing now.
To accuse T Frudakis of multialiases ,etc., etc is ridiculous.The guy had a dream. Period. If some of you want to strech this out into diferious speculation, just go ahead.
But nobody has even asked about Ellipses in Canada and Trace. It is amazing that stockholders don't even have a clue about the businesses they own or the status quo of these enterprises
These businesses actually have , (or had) employees.
Good luck to you all.
The idea was great and that is all there is.
Get over it.
The long-term shareholders who hang here seem to be passe about the status quo and will now accept whatever comes along. All the unsupported suppositions about company cheats and unpaid rents and stolen patents have proven to be negative hyperbole and have not been substantiated. The "rent-not-paid" assumption was put to rest by the landlord himself. That was a nasty rumor to start, IMO.
DnaPrint is broke. Duh. DnaPrint is not dead. If it dies, I would just like it to die on it's own without extra help.
Yet there seems to be a desperation to put a final fate accompli into this company by a certain element. I guess that five one-hundreths of a cent per share is not good enough. Why you would enter a message board when the stock is that low,(december) and then become totally familiar with all the negatives and then pound away at them is beyond me.
The stock price says everything. But I suppose this element is here to keep us from using our investment dollars unwisely. Thank you for that.
Mr "Tirebiter"
And since when does the absence of information allow any one person to create the most damaging scenario involving a company and release it on a forum made for investors of that company?
These "suppositions" are way out of line and unsubstantiated.
DNAP Landlords
Yonker Investments
Jack Yonker
8230 Abingdon Ct
Bradenton, FL 34201
(941) 360-1560
For anybody who wants to track down DNAP's landowner and ask them the rent status:
Manatee County Property Search
PARCEL INFORMATION
Parcel ID Number: 2024200004
Primary Owner: YONKER INVESTMENTS INC
Primary Address: 1621 WEST UNIVERSITY PKY
Secondary Addresses: CLICK HERE
Place Code: 34243
Section/Township/Range: 31/35/18
Map Number: 5CS3 1
Acres: 2.7691
DOR Use Code: 4100
DOR Description: LIGHT INDUSTRIAL
Zoning: HM
Short Legal Description: THE E1/2 OF FOL DESC LAND: THE WLY 400 FT OF S1/2 OF SW1/4 OF SE1/4 OF SEC 31 DESC AS FOL: BEG AT SE COR OF SEC 31; TH
Long Legal Description: CLICK HERE
Fire District: SOUTHERN MANATEE FIRE DISTRICT
And in the last ten years all the "making" has been done by "monsters".
Another false run would be right in the timeline.
But.......just maybe......someday......
The wolves wouldn't be sniffing at the door and circling the house unless there was meat inside.
Coming after your shares or trying to kill the company is a good sign.
Well, it's been almost a year since this article. It would be nice to know if it is still in the works....
BioServe, DNAPrint to Develop Ovarian Cancer Dx to ID Best Chemo Responders
March 12, 2008
By Turna Ray
Type size: -+
Email
RSS Feed
BioServe and DNAPrint are collaborating to develop a pharmacogenetic diagnostic designed to help doctors identify which ovarian cancer patients will respond best to carboplatin/Taxol-based chemotherapy.
Under an ongoing collaboration penned in 2003, BioServe provided DNAPrint with clinical samples for an ovarian cancer study. According to a BioServe spokesperson, “validation is now occurring towards [developing] a PGx application,” called Ovanome, that will be launched in the first quarter of 2009.
In order to help DNAPrint develop the test, BioServe used its physician network to prospectively identify patients on a particular therapy and perform follow-up interviews to determine the treatment outcome.
“This was crucial for DNAPrint to identify the genetic markers that correlated to the response to a specific treatment,” the BioServe spokesperson told Pharmacogenomics Reporter this week.
DNA Print scientists have identified several SNP markers whose haploid alleles are predictive for non-response to the carboplatin/Taxol combination treatment. The company did not provide additional details on the test prior to deadline.
Separately, BioServe is helping DNAPrint to gauge the response of hypertensive patients to treatment with Lipitor and other statins used to treat HT.
According to a BioServe spokesperson, the company has been involved with a number of statin studies investigating myalagia, a muscle-related adverse event, as well as other side effects.
DNAPrint submitted a study to the American Association for Cancer Research this year that investigated whether common SNPs are associated with the expression of broadly grouped atorvastatin-induced muscle events. The company looked at 263 samples and 388 SNPs and found that the CYP2D6*4 allele was significantly associated with muscle events.
“The adoption of personalized medicine on a large scale requires the identification of biomarkers … and the ability to pre-clinically validate those markers in human models before embarking on high-risk, high-cost clinical trials with confidence.”
“The frequency of the CYP2D6*4 allele was about 50 percent in atorvastatin-induced muscle patients but only 28 percent in controls, similar to that of other patient types (28.5 percent),” the abstract states. “Our results suggest that the CYP2D6*4 allele is associated with broadly related muscle events caused by at least two structurally dissimilar HMG-CoA reductase inhibitors, and as such, may have implications for a better understanding of this statin-wide phenomena.”
Pharma Collaborations
BioServe's collaboration with DNA Print is one in a number of research efforts the company is undertaking with drug, biotechnology, and diagnostic companies. BioServe said that in the second half of 2007 it signed 211 agreements with several biotechnology and pharmaceutical companies, including Novartis, Sanofi-Aventis, and Genentech, as well as research organizations, including the Broad Institute, the National Cancer Institute, Baylor University, and Health Canada.
According to the BioServe spokesperson, the company currently works with 28 of the 30 large pharma companies with more than $3 billion in revenue or with R&D expenditure of $500 million or more. Its collaborations with pharmas have been bolstered by its acquisition of Genomics Collaborative in May 2007. Since the acquisition, BioServe has acquired 76 new customers, the company reported.
“The adoption of personalized medicine on a large scale requires the identification of biomarkers … and the ability to pre-clinically validate those markers in human models before embarking on high-risk, high-cost clinical trials with confidence,” the BioServe spokesperson explained.
This is where BioServe's platform — which includes CLIA-certified genomic and molecular processing services and a global biobank of 1.5 million human tissue, DNA, blood, and serum samples from 140,000 patients — helps customers identify, validate, and process biomarkers for drug and diagnostic development.
In 2008, the company plans to introduce several bio-sample and processing products “to increase the utility and application of human bio-samples for a larger portion of the research and development community,” BioServe said in a statement.
I had a post removed, but want to reiterate the fact that there has been this talk of DnaPrint being a scam , so that the officers can "dump shares".
In the last two years there has not been enough shares authorized and sold to pay for one person's salary, much less support a "scam". These accusations are misleading and bordering on libel.
"No connection" means no mutual research, no mutual officers, no scientific relations whatsoever?
Would like to see the proof of that.
And please, no more "IBM" examples.
Note;
Frogdreaming has stated that DNAG "has no connection with Biofrontera".
These kind of statements are made without a shred of evidence. Frogdreaming has no basis or reason to make this statement other than to expose an agenda.
If anyone has any proof that there is no connection whatsoever to Biofrontera, I would appreciate a post indicating just that. Even if Gabriel has left the company, which we have no way of knowing, work may still be done with Biofrontera. Deductive reasoning does not qualify for such a statement.
With all "due" respect, Porgie,
Tell us something we DON'T know.
Thanks, but...........no thanks.
Bag & Daniel,
Howdy Bag! How the heck are ya?
Actually, I think we have three now. They will pick whatever meaningless little nugget of trouble they can and pound away at it, trying to pester (in this case) Daniel right out of the stock. I have a feeling though, that he is onto their tactics.
I am sure that someone coming along and buying up miliions and millions of shares wasn't in the plan. I love this.
I still have 11 million. Until it turns to dust!
Insider, inshmider. Gift, smift.
Hang in there boys!
An alternative to "shooting the messenger" because you don't like the message would be to do your own DD.
Don't ask for someone's time and information while denigrating the forum.
No one here has posted any revenue figures for over a year, fyi.
Porgie,
1. Do not mistake enthusiasm for pumping. The forensics product from this company has very likely helped save a life or two. The event of Anne's murder and methods to catch her killer are two different subjects.
2.The company has probably just enough revs to run the front office.
DG,
Years ago, we all sat here and watched DNAP stock go to eighteen cents in one day as the news came out on the use of our forensics test to help catch the Louisiana serial murderer.
There will be no replay. Yet it is still good press for the company, in many respects.
There was another California case a couple years later that DNAP helped solve, and there was very little reaction both in the media and the stock price.
After being here for eight years, it is obvious that revenues will be the only factor that lifts DNAPrint off the floor. Your commitment to the company is to be commended, along with your patience exhibited in respect to the "naysayer".
It doesn't matter at this point if DNAwitness was used in the Anchorwoman's case.
We all know there are many kits out there used in law enforcement agencies that will
bring some exposure and some revenues to DNAG both now and in the future..
The reality is that it will take alot more than forensics, ancestry tests and even Daniel Gannon to make DNAG a viable company. We need a breakthrough in our pharmaceutical applications and that is all there is to it, financing included.
Divide all the potential revenues that come from Ancestry and Forensics by a billion shares and what do you get.
The naysayer will press the negative to the ultimate goal. Don't give the naysayer more fodder.
Opportunity of a lifetime.
Copied from a week ago:(dgplexis,9/05)
"In the interest in complete disclosure, and not just disclosing things that we all want to hear, I've found out today, that the DNAG outstanding share count has increased recently. I called the registrar:
Standard Registrar & Transfer
12528 S 1840 E, Draper, UT 84020-9100, United States
Phone: (801) 571-8844
http://www.manta.com/coms2/dnbcompany_ccwjjdk
They informed me the current outstanding share count is:
1,113,790,464.2
Presently I own a little less than 10% of the stock, and I've been buying many of these shares, that were recently issued. I'm fine with that, as I'm willing to help finance DNAPrint Genomics, within my means.
We still haven't gone back to the .0002 lows. I view that as a notable development, in the stock price. I think the emerging news, especially about the healthy number of distributors, has a lot to do with that.
I'm still prepared to accumulate more shares of DNAG. I view this as a tremendous opportunity, and I'm not scared off by a normal function like a company issuing shares to raise needed funds, especially when that company is DNAPrint Genomics, and has demonstrated such a lean burn rate on the funds. You've got to pay to play, as they say. Not everyone welcomes this, but it's facing reality. I wouldn't be honest if I didn't report all of the news, popular and unpopular.
Good luck to all DNAG shareholders. I'm still confident that our chances of success are very good, and that the potential upside far outweighs the potential downside.
Still in the running with DNAG,"
This is like going to a self-pity convention. Life is short. There is nothing to gain by blaming others for our own risk-taking. I haven't started to wallpaper the b-room yet with my shares, but won't cry over spilt milk either. Regards.
Except for the fact that you and your entourage have been screaming DNAPrint is dead, while Louise is still working. It is obvious the business is still operating on some level. The doors are not closed completely.
Does this irk the naysayers?
Just when you think there is no blood left in the carcass, a few "unborne flies" will gather like sharks and try to posse up few fools to take pennies from. In the same way there are those who, despite the fact that their axes have been ground to the hilt, will find yet, (and with unabated furor) an opportunity to perspire some cancerous venom that you would think had long abated.
"Company Shills"? Uh, yeah,.......rght. Once again the company is blamed for the foul deed of destroying itself thru stock manipulation.
How convenient. How easy.
Grind that axe to the hilt.
How are you Bag?
I have never seen "sheep" roll dice before. Rather interesting. If the "sheep" here won't listen to the angry screams of one investor, maybe he should go to Las Vegas and tell everybody there how he got ripped off trying to gamble with a penny stock.
Take your lumps. Life is short. Good luck to you.
So someone bought a 12 million share hunk today. Hmm.
Double "ditto". eom
Personally, I feel frustrated that there is just not enough time to come here and bad mouth this company every day, as I am sure it would improve my disposition and make useful time
spent wisely. Living in the negative world is a great goal in life, and taking risks and blaming others is the keen thing to do. I'll keep my 10 million shares anyday compared to being a sorry-whining complainer and spewing slander.
I'll check back in a week. You just never know......
I guess you all knew that you were investing in a blue chip stock. There was no risk, right?
Every single SEC report warned investors. Yet some just can't blame themselves. It has to end up that the company was a scam so some can save face.
I do not believe Gabriel and Frudakis had bad intentions.
You can worship Frogs and Diamonds all you want.
The good news is that even though the drug reduced overall Cholesterol & Triglycerides, it had no affect on Plaque, and we may come to find out in the future that other statins don't have that much affect against plaque, which would support the theories of "slow" bacteria-driven calcification,
something NNBP claims to be proving. Should be interesting.
Don't understand why you would think the deal would be dead because of the NNBP news. All the more reason to need DNAG ,imo.
Sam's got it right. Just think of the Life of Brian when Brian is on the cross being crucified because they think he's Jesus. Do you remember him singing, "look on the bright side of life...."?(monty python)
I actually take pleasure in this moment in time, where DNAG death is a forgone conclusion and there are no more percieved investors to torture, leaving us with a peaceful, if not resigned, board that is numb with deflation yet spent with the exhaustive whining of those who yell "scam" in leiu of placing risk-taking blame on their own greed. Oh, how rationalization will create truth out of need of sense.
DnaPrint is not dead yet.